Hims & Hers is one of the leading telehealth firms in the US. Since its 2017 launch, the platform has connected patients with healthcare providers across specialties including erectile dysfunction, hair loss, and weight loss. Subscribers have soared from 290,000 at the end of 2020 to over 2.7 million in 2026, with roughly half of the growth driven by the late-2023 launch of the weight-loss program.
An increasing shift to digital healthcare underpins long-term growth potential for Hims’ subscribers.
Failure to optimize customer acquisition costs could weigh down subscriber growth and put pressure on margin, two figures crucial to Hims’ long-term targets.
Metric | HIMS | PRGO | NVO |
|---|---|---|---|
Price/Earnings (Normalized) | 573.11 | 6.50 | 10.32 |
Price/Book Value | 13.02 | 0.92 | 5.56 |
Price/Sales | 1.65 | 0.55 | 3.56 |
Price/Cash Flow | 29.52 | 11.14 | 9.37 |
Metric | HIMS | PRGO | NVO |
|---|---|---|---|
Quick Ratio | 0.79 | 1.10 | 0.63 |
Current Ratio | 0.92 | 2.35 | 0.84 |
Interest Coverage | — | −9.30 | — |
Metric | HIMS | PRGO | NVO |
|---|---|---|---|
Return on Assets (Normalized) | −1.98% | −2.77% | 20.15% |
Return on Equity (Normalized) | −12.16% | −7.79% | 56.25% |
Return on Invested Capital (Normalized) | −3.13% | −1.41% | 33.34% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|^JJsth&< | LOCK|?lKDT | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|?c<d&<X | LOCK|n??%? | $51B | |||
| Haleon PLC ADR HLN | LOCK|JYg&dB& | LOCK|Y^ | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|Z!&%&xb% | LOCK|wC> | $34B | |||
| Viatris Inc VTRS | LOCK|Gb#%&w@ | LOCK|yWK | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|W&m | LOCK|zBD | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|?G#z<^ | LOCK|@%G | $12B | |||
| Perrigo Co PLC PRGO | LOCK|kcfQfp | LOCK|$p | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|l!G^?v | LOCK|C%PR? | $2B |
United States